Journal of Inflammatory Bowel Diseases & Disorders deals with large intestine and small intestine inflammatory conditions like Ulcerative colitis, Crohn’s disease, Colon cancer, Collagenous colitis and lymphocytic colitis. Journal of Inflammatory Bowel Diseases & Disorders is a peer-reviewed international journal that publishes scientific articles related to diagnosis, treatment and management of Bowel Diseases and disorders. The journal established in 2016 is currently running Volume 6, issue 4. The previous volume 6, issue 2 discussed about various aspects regarding the journal scope. The issue consisted of 5 different types of articles (Editorial, Opinion Article, Research Article, Mini Review and Perspective article) which are available freely in online with high quality peer reviewed articles.
Fecal Microbiota Transplantation (FMT) is one of the emerging strategies against many diseases related directly to the branch of gastroenterology, infectious diseases, hematology or transplantation. Along with mounting new ideas about possible indications for FMT, there are growing challenges as well.
Inflammatory bowel disease (IBD) is an idiopathic sickness brought about by a dysregulated safe reaction to have intestinal microflora. The two significant sorts of provocative entrail sickness are ulcerative colitis (UC), which is restricted to the colon, and Crohn illness (CD), which can influence any section of the gastrointestinal lot from the mouth to the butt, includes skip injuries, and is transmural. There is a hereditary inclination for IBD, and patients with this condition are more inclined to the advancement of danger. Celiac Disease, Colon Cancer, Lymphocytic Colitis, Bowel Endometriasis, intestinal endometria etc., also come under inflammatory bowel diseases.
The award is designated for the Masters/Ph.D./ Post Doctorate students who can present their thesis and projects or have executed the same for the long term excellence in the field of GI Diseases. Deserving nominees can be awarded online as well.
Anti-microbial Resistance happens when microorganisms (like microscopic organisms, organisms, infections, and parasites) change and are yet ready to develop, in any event, when they are presented to antimicrobial prescriptions that are intended to execute or restrict their development.
Gastrointestinal Diseases GI Diseases Market is expected to grow from USD 17.27 billion in 2016 and reach USD 19.79 billion in 2022, growing at a CAGR of 2.3% during the forecast period.
Many epidemiological studies have searched for the elements that may shed light on the etiology of IBD, particularly in pediatric siblings. Researcher aims to study about the pediatric siblings ,nflammatory Bowel Disease (,B').Нe findLnJs state that antibiotic exposure or other environmental factor may be responsible for the present cause
In the past 20 years, a gastro-intestinal complex has emerged that has been tentatively linked to Small Intestinal Bacterial Overgrowth (SIBO). The symptoms of constipation or diarrhea, bloating and distress, even to the level of cachexia have been presumed to be from bacterial overgrowth of methane producing Achaea bacteria including Methanobacteriales oralis and Methanobacteriales smithii. However, the SIBO symptom complex that was initially reported to be responsive to rifaximin and neomycin antibiotic therapy has subsequently become more and resistant leaving both patients and treating physicians in a quandary. The author was asked to consult on 18 patients whom had disruptive gastrointestinal symptoms, positive SIBO breathe test and repeated failure to respond to courses of primarily rifaximin therapy. These patients were overwhelming female and fell into the newly described field of Gender Specific Medicine (GSM). The biomarker for decreased bioavailable testosterone is the Free Androgen Index (FAI) in both sexes. Serum dysregulation included the gambit of hormonal assays: hypothyroidism, Hashimoto’s thyroiditis, menopause, male hypogonadism, adrenal fatigue and low levels of vitamin D3 (Cholecalciferol). These patients had an unexpected high incidence of gastrointestinal autoimmunity including pernicious anemia, hyperchlorhydria per the Heidelberg test and autoimmune gastritis. Treatment was naturopathic, non-gonadal hormonal and when all else failed, in systemic anabolic hormone replacement, patient improvement did not reach the 75 percent threshold required in the study. Therefore, the protocol of mixed anabolic steroid replacement was initiated subsequently.
We describe the case of a 40-year-old patient with active Crohn’s Disease (CD)-who developed neurological symptoms and was subsequently diagnosed with cerebral demyelination shortly after re-exposure to a therapy with Adalimumab. Based on the current state of scientific knowledge, we here discuss whether concurrent diagnosis of demyelinating disease and the anti-tumor-necrosis-factor (TNF)-alpha-therapy develop independently or whether direct causality is more likely. Basis for this purpose are the diseases´ incidence rates and the different pathophysiological hypotheses for demyelination under anti-TNF-alpha-therapy. Due to high incidence of cerebral demyelination and lack of laboratory or clinical markers to differentiate the underlying influences, a definite conclusion cannot be drawn. Based on the presented findings and state of the literature, we finally deduce recommendations for clinical practice and research gaps.
The etiology of Inflammatory Bowel Diseases (IBD), which comprise predominantly of two types as Crohn's infection and ulcerative colitis, is at this point unclear. Nonetheless, increasingly more proof shows gut microflora has a significant influence in starting and keeping up the mucosal provocative reaction in IBD.
Inflammatory Bowel Disease (IBD) is a challenging medical condition that is driven by various genetic and environmental factors. Therapeutic opportunities for this disease remain limited due to the lack of in-depth understanding of the pathogenetic mechanisms and actionable targets driving the disease. Analysis of telomere dysfunctional mice and patients with genetic defects in telomere maintenance unexpectedly revealed phenotypes mirroring those observed in IBD. Molecular characterization of this model identified a pathway driven by telomere DNA damage-mediated activation of the ATM/cABL/YAP1 pathway, which directly regulates genes central to IBD pathogenesis and amenable to therapeutic intervention. This review summarizes the evidence correlating telomere dysfunction with IBD and colitis-associated cancer and proposes therapeutic opportunities for such inflammatory conditions targeting this newly identified pathway.
Journal of Inflammatory Bowel Diseases and Disorders is an openaccess Peer-Reviewed journal that seeks to publish the latest and excellent research papers, reviews and letters in all bowel and gastro related disorders. Submissions will be assessed on their scientific validity and merit.
Proton Pump Inhibitors (PPIs) are the most generally endorsed class of medicine for the treatment of indigestion and corrosive related issues. They work by obstructing the site of corrosive creation in the parietal cell of the stomach. Infliximab, a chimeric monoclonal antibody, is a medication used to treat a number of autoimmune diseases mainly Ulcerative Colitis (UC) and Crohn's Disease (CD). Infliximab targets TNF, thought to be more related to Th1 cytokines.
The increasing evidence regarding TE events and risk factors in IBD patients demands a better disease control in order to reduce these feared vascular complications.Additionally, a higher or should be evoked to increase the rate of venous TE prophylaxis in IBD inpatients.
Background:The global incidence of Inflammatory Bowel Disease (IBD), Ulcerative Colitis (UC) and Crohn's Disease (CD), is in the rise. Despite the presence of some international studies that described the different patterns and characteristics if IBD, still however, we don't have a national epidemiological or descriptive data especially in Gaza Strip. The aim of this study is to identify socio-demographic and clinical characteristics of IBD among patients with IBD in Gaza.
Ulcerative colitis is a major form of chronic inflammatory bowel disease affecting millions of individuals worldwide. It most often strikes in the prime of life, during late adolescence and early adulthood. Individuals with ulcerative colitis experience life-long reoccurring and unpredictable episodes of abdominal pain and bloody diarrhea lasting from weeks to months. This results in significant emotional and psychological burdens leading to life-long disruption of daily activities and quality of life. Environmental factors acting in concert with genetic, epigenetic, and microbiome influences are thought to trigger an immune abnormality leading to the chronic colonic inflammation observed in this condition. However, despite extensive research, a primary antecedent immune vulnerability has not been demonstrated in patients or healthy family members. Current therapy is primarily focused on suppressing or modulating the immune response, which is not curative. Other therapeutic modalities such as fecal microbiota transplantation and probiotics are not recommended as viable therapy options. Recent experimental data suggest a build-up of hydrogen peroxide in colonic epithelial cells as a causal factor in the development of this disease. Herein we describe a patient with a 39-year history of ulcerative colitis refractory to standard medical therapy including oral and rectal 5-aminosalicylic acid, oral and rectal steroids in addition to immunosuppressive agents such as 6-mercaptopurine. The patient received the recommended doses of these medications for months at a time in varied combinations without significant improvement. He subsequently received a novel combination therapy aimed at reducing colonic hydrogen peroxide. Histologic remission was achieved 6 weeks after this initial therapy. Colonoscopic evaluation 12-years after initial therapy revealed complete and sustained mucosal healing with histologic restitution to normal colonic mucosa. The patient reports having normal bowel movements during this 12-year period.
Background: Anemia is a common extra-intestinal manifestation of inflammatory bowel disease. The magnitude of anemia in Inflammatory Bowel Disease (IBD) patients and the risk factors were not previously studied from Saudi Arabia. Objectives: Objectives of the study were to find prevalence of anemia, etiology and its risk factors. Design: Retrospective cohort study Setting: Hospitalized patients at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia Patients and methods: The data pertaining to anemia was collected from IBD patients between 2000 to 2018, at the time of first presentation to the hospital, and the lowest hemoglobin during the follow up. Anemia was diagnosed if hemoglobin (Hb) level was below 13 g/dl in males and below 12 g/dl in females. Severe anemia was defined as Hb <10 g/dl for both genders. Patients were further classified into iron deficiency anemia, Anemia of Chronic Disease (ACD), based on c-reactive protein and serum ferritin levels. Vitamin B12 deficiency was diagnosed if the vitamin B12 level was <150 pg /ml. Main outcome measures: Prevalence of anemia, etiology and its risk factors in IBD patients Results: From 190 patients IBD screened, 109 patients were included, 56% were males. Crohn's disease was in 77 (70.6%) and ulcerative colitis in 32 patients (29.4%) At the time of first presentation to the hospital, 51.4% of patients had anemia, and during the median follow-up of 759 days, 62.4% of our cohort were diagnosed with severe anemia. Iron deficiency anemia was diagnosed in 13.8%, ACD was diagnosed in 3.7%, and iron deficiency plus ACD was diagnosed in 2.8%. From 101 patients, 26 of them (23.9%) had vitamin B-12 deficiency. No identifiable risk factors were found at the time of presentation for anemia in IBD population. Binary logistic regression analysis showed female gender (p-value 0.001) and anemia at presentation (p-value 0.0001) were risks for subsequent development of severe anemia. Conclusion: Anemia in IBD population is highly prevalent. Female gender and anemia at presentation are risks for the development of severe anemia in IBD population. Limitations: Hospital based retrospective study.
Amebiasis affects around 500 million people in the world and could lead to 100,000 deaths/year from amebic dysentery and/or liver abscess. It is prevalent in developing countries like the Southern and Eastern Mediterranean region, and more in the Indian subcontinent, Southern and Western Africa and South America where prevalence could reach 50%. It is mainly caused by Entamoeba Hystolitica (EH). Underlying conditions associated with immunosuppression including diabetes mellitus and tuberculosis are present in more than 50% of patients.
Coffee consumption has its benefits on human health. In the specific area of hepatology, previous studies have suggested that coffee decreases liver enzymes and inhibits progression of liver fibrosis. Additionally, in a recent systematic review and meta-analysis, coffee consumption was shown to have an inverse association with the development of liver cancer. That well-designed study suggested that coffee drinking would be beneficial in terms of preventing liver cancer. Coffee drinkers at risk of developing hepatocellular cancer should consider the potential benefits of drinking coffee
